<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888901</url>
  </required_header>
  <id_info>
    <org_study_id>IP-001</org_study_id>
    <secondary_id>Eltrombopag 112650</secondary_id>
    <nct_id>NCT00888901</nct_id>
  </id_info>
  <brief_title>Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag</brief_title>
  <acronym>PLATEFUN</acronym>
  <official_title>Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ingrid Pabinger, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, controlled study with one eltrombopag treatment group&#xD;
      and 2 control groups, one on standard steroid treatment, and another one untreated.&#xD;
&#xD;
      The aim of the study is to determine the effect of Thrombopoietin Receptor (MPL) agonists on&#xD;
      shear-induced platelet activation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN:&#xD;
&#xD;
      Single-center (Medical University Vienna), prospective, controlled study. Patients will be&#xD;
      recruited at the Division of Haematology and Haemostaseology at the Medical University in&#xD;
      Vienna, one eltrombopag treatment group and 2 control groups, one on standard steroid&#xD;
      treatment, another one untreated.&#xD;
&#xD;
      AIM OF THE STUDY:&#xD;
&#xD;
      To determine the effect of MPL agonists on shear-induced platelet activation. Data obtained&#xD;
      from patients treated with eltrombopag shall be compared to those from untreated patients and&#xD;
      patients on steroids. These investigations will extend previous studies that investigated&#xD;
      platelet function without in vitro activation in patients receiving eltrombopag.&#xD;
&#xD;
      PATIENTS:&#xD;
&#xD;
      Trial Population:&#xD;
&#xD;
      Total number of patients n=34: 12 on eltrombopag, 12 on corticosteroids and 10 without&#xD;
      treatment will be included in this trial.&#xD;
&#xD;
      Treatment with eltrombopag or corticosteroids. Eltrombopag starting dose: 25 mg/day,&#xD;
      increased as needed (to 50 mg or maximum 75 mg once daily) every 2 weeks to reach a platelet&#xD;
      count between 50,000-100000/µL and tapering the dosis if platelet count &gt;= 100,000/µL.&#xD;
      Afterwards, if platelet count stable (tolerance +/- 20%), platelet control every 4 weeks,&#xD;
      otherwise weekly.&#xD;
&#xD;
      Prednisolone starting dose: 1 mg/kg/day to reach a platelet count between 50,000-100,000 /µL&#xD;
      tapering of the dosage if platelet count &gt;= 100,000/µL.&#xD;
&#xD;
      Laboratory Investigations:&#xD;
&#xD;
      In the eltrombopag group and in the newly treated prednisolone group platelet counts and&#xD;
      platelet function tests will be performed at planned visits.&#xD;
&#xD;
      In patients who are on continuous corticosteroids (part of control group I) and untreated&#xD;
      patients (control group II), which have a platelet count between 50,000 and 100,000/µL&#xD;
      platelet counts, reticulated platelets, platelet function tests and platelet antibodies will&#xD;
      be studied at entry and after 4 weeks (+ 5 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The shear-induced platelet activation (SC) is considered as the primary outcome measure.</measure>
    <time_frame>After an average of 2-4 weeks, when patient has a platelet count between 50,000 and 100,000/µL.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rise of reticulated platelets and variation of platelet antibodies.</measure>
    <time_frame>After an average of 2-4 weeks, when patient has a platelet count between 50,000 and 100,000/µL.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on eltrombopag</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients on corticosteroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eltrombopag</intervention_name>
    <description>eltrombopag tablets daily, in increasing dosage, for three months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>SB-497115-GR, Promacta (USA), Revolade (EU)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticosteroids (Aprednislon)</intervention_name>
    <description>corticosteroids in decreasing dosage</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Aprednislon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (for all groups):&#xD;
&#xD;
          -  Male and female patients with an established chronic autoimmune thrombocytopenia&#xD;
             (cAITP)&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 90 years&#xD;
&#xD;
          -  Females, if not pregnant, not nursing and consenting to perform safe&#xD;
             anti-contraception&#xD;
&#xD;
          -  Written consent before any study related procedure&#xD;
&#xD;
        Inclusion Criteria (for patients treated with eltrombopag):&#xD;
&#xD;
          -  Platelet count &lt; 50,000 /µL at screening&#xD;
&#xD;
          -  At least one prior alternative cITP therapy&#xD;
&#xD;
        Inclusion Criteria (for patients treated with corticosteroids - Control group 1):&#xD;
&#xD;
          -  Platelet count &lt; 50,000 /µL in history&#xD;
&#xD;
          -  At least 50% of the patients should have &lt; 50,000 /µL at inclusion and should be&#xD;
             followed for 3 months&#xD;
&#xD;
        Inclusion Criteria (for patients untreated - Control group 2):&#xD;
&#xD;
          -  Platelet count &lt; 50,000 /µL in history&#xD;
&#xD;
          -  At screening platelet count between 50,000 and 100,000 /µL&#xD;
&#xD;
        Exclusion Criteria (for all patients):&#xD;
&#xD;
          -  History of venous or arterial thromboembolism or stroke&#xD;
&#xD;
          -  Known coronary heart disease or cardiac arrythmias&#xD;
&#xD;
          -  Known HIV or Hepatitis C infection&#xD;
&#xD;
          -  Impaired liver function defined as elevated ALT &gt; 1.5 UNL, bilirubin more than ULN,&#xD;
             albumin less than normal value&#xD;
&#xD;
          -  Prothrombin time less than normal value&#xD;
&#xD;
          -  Elevated creatinine level (&gt; 1.3 ULN)&#xD;
&#xD;
          -  Unable/unwilling to follow protocol&#xD;
&#xD;
          -  Previous or active malignancy&#xD;
&#xD;
          -  Patients who have been included in any other study with eltrombopag any time before&#xD;
&#xD;
          -  Patients treated with another investigational product within the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid Pabinger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <link>
    <url>http://www.meduniwien.ac.at/haematology/</url>
    <description>Division of hematology and hemostaseology, Med. Univ. Vienna</description>
  </link>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Ingrid Pabinger, MD</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>ITP</keyword>
  <keyword>eltrombopag</keyword>
  <keyword>platelet function</keyword>
  <keyword>thrombocytopenia</keyword>
  <keyword>Platelet function in patients with cAITP on eltrombopag</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 19, 2012</submitted>
    <returned>January 24, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

